Research Analysts’ Weekly Ratings Changes for REGENXBIO (RGNX)

A number of research firms have changed their ratings and price targets for REGENXBIO (NASDAQ: RGNX):

• 8/12/2026 – REGENXBIO was upgraded by Zacks Research from “strong sell” to “hold”.
• 8/10/2026 – REGENXBIO had its price target lowered by HC Wainwright from $26.00 to $23.00. They now have a “buy” rating on the stock.
• 8/8/2026 – REGENXBIO was upgraded by Wall Street Zen from “strong sell” to “hold”.
• 8/7/2026 – REGENXBIO had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $18.00 price target on the stock.
• 8/7/2026 – REGENXBIO was downgraded by Barclays PLC from “overweight” to “hold”.
• 8/7/2026 – REGENXBIO had its “equal weight” rating reaffirmed by Barclays PLC. They now have a $12.00 price target on the stock.
• 7/14/2026 – REGENXBIO was downgraded by Zacks Research from “hold” to “strong sell”.
• 7/1/2026 – REGENXBIO had its “buy” rating reaffirmed by HC Wainwright. They now have a $26.00 price target on the stock.
• 6/24/2026 – REGENXBIO had its “buy” rating reaffirmed by HC Wainwright. They now have a $26.00 price target on the stock.
• 6/22/2026 – REGENXBIO had its price target raised by Leerink Partners from $17.00 to $18.00. They now have an “outperform” rating on the stock.
• 6/22/2026 – REGENXBIO had its price target raised by Robert W. Baird from $27.00 to $32.00. They now have an “outperform” rating on the stock.

Insider Activity

In other news, insider Steve Pakola sold 36,725 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $12.86, for a total transaction of $472,283.50. Following the transaction, the insider owned 213,009 shares of the company’s stock, valued at $2,739,295.74. This represents a 14.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders sold a total of 58,494 shares of company stock worth $718,232 over the last quarter. Corporate insiders own 14.22% of the company’s stock.

Get REGENXBIO Inc alerts:

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.

See Also

• Five stocks we like better than REGENXBIO
• Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
• Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
• NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
• Sandisk’s Margins Look Like Software. Can They Last?

Receive News & Ratings for REGENXBIO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc and related companies with MarketBeat.com's FREE daily email newsletter.